Search This Blog

Thursday, December 13, 2018

Imprimis initiated at B. Riley FBR


Imprimis initiated with a Buy at B. Riley FBR. B. Riley FBR analyst Andrew D’Silva started Imprimis Pharmaceuticals with a Buy rating and $11.50 price target.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)